Cargando…

Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior

BACKGROUND: Vascular homeostasis is ensured by a dynamic interplay involving the endothelium, the platelets and the coagulation system. Thus, the vascular safety of particulate materials must address this integrated system, an approach that has been largely neglected. This work analysed the effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Catarina, Turiel, Suzy, Sousa Gomes, Pedro, Costa, Elísio, Santos-Silva, Alice, Quadros, Paulo, Duarte, José, Battistuzzo, Sílvia, Fernandes, Maria Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863823/
https://www.ncbi.nlm.nih.gov/pubmed/29566760
http://dx.doi.org/10.1186/s12951-018-0357-y
_version_ 1783308440223875072
author Santos, Catarina
Turiel, Suzy
Sousa Gomes, Pedro
Costa, Elísio
Santos-Silva, Alice
Quadros, Paulo
Duarte, José
Battistuzzo, Sílvia
Fernandes, Maria Helena
author_facet Santos, Catarina
Turiel, Suzy
Sousa Gomes, Pedro
Costa, Elísio
Santos-Silva, Alice
Quadros, Paulo
Duarte, José
Battistuzzo, Sílvia
Fernandes, Maria Helena
author_sort Santos, Catarina
collection PubMed
description BACKGROUND: Vascular homeostasis is ensured by a dynamic interplay involving the endothelium, the platelets and the coagulation system. Thus, the vascular safety of particulate materials must address this integrated system, an approach that has been largely neglected. This work analysed the effects of commercial hydroxyapatite (HA) particles in blood compatibility and in endothelial cell behavior, due to their clinical relevance and scarcity of data on their vascular biosafety. RESULTS: Particles with similar chemical composition and distinct size and morphology were tested, i.e. rod-like, nano dimensions and low aspect ratio (HAp1) and needle-shape with wider size and aspect ratio (HAp2). HAp1 and HAp2, at 1 to 10 mg/mL, did not affect haemolysis, platelet adhesion, aggregation and activation, or the coagulation system (intrinsic and extrinsic pathways), although HAp2 exhibited a slight thrombogenic potential at 10 mg/mL. Notwithstanding, significantly lower levels presented dose-dependent toxicity on endothelial cells’ behavior. HAp1 and HAp2 decreased cell viability at levels ≥ 250 and ≥ 50 μg/mL, respectively. At 10 and 50 μg/mL, HAp1 did not interfere with the F-actin cytoskeleton, apoptotic index, cell cycle progression, expression of vWF, VECad and CD31, and the ability to form a network of tubular-like structures. Comparatively, HAp2 caused dose-dependent toxic effects in these parameters in the same concentration range. CONCLUSION: The most relevant observation is the great discrepancy of HA particles’ levels that interfere with the routine blood compatibility assays and the endothelial cell behavior. Further, this difference was also found to be dependent on the particles’ size, morphology and aspect ratio, emphasizing the need of a complementary biological characterization, taking into consideration the endothelial cells’ functionality, to establish the vascular safety of particulate HA.
format Online
Article
Text
id pubmed-5863823
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58638232018-03-27 Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior Santos, Catarina Turiel, Suzy Sousa Gomes, Pedro Costa, Elísio Santos-Silva, Alice Quadros, Paulo Duarte, José Battistuzzo, Sílvia Fernandes, Maria Helena J Nanobiotechnology Research BACKGROUND: Vascular homeostasis is ensured by a dynamic interplay involving the endothelium, the platelets and the coagulation system. Thus, the vascular safety of particulate materials must address this integrated system, an approach that has been largely neglected. This work analysed the effects of commercial hydroxyapatite (HA) particles in blood compatibility and in endothelial cell behavior, due to their clinical relevance and scarcity of data on their vascular biosafety. RESULTS: Particles with similar chemical composition and distinct size and morphology were tested, i.e. rod-like, nano dimensions and low aspect ratio (HAp1) and needle-shape with wider size and aspect ratio (HAp2). HAp1 and HAp2, at 1 to 10 mg/mL, did not affect haemolysis, platelet adhesion, aggregation and activation, or the coagulation system (intrinsic and extrinsic pathways), although HAp2 exhibited a slight thrombogenic potential at 10 mg/mL. Notwithstanding, significantly lower levels presented dose-dependent toxicity on endothelial cells’ behavior. HAp1 and HAp2 decreased cell viability at levels ≥ 250 and ≥ 50 μg/mL, respectively. At 10 and 50 μg/mL, HAp1 did not interfere with the F-actin cytoskeleton, apoptotic index, cell cycle progression, expression of vWF, VECad and CD31, and the ability to form a network of tubular-like structures. Comparatively, HAp2 caused dose-dependent toxic effects in these parameters in the same concentration range. CONCLUSION: The most relevant observation is the great discrepancy of HA particles’ levels that interfere with the routine blood compatibility assays and the endothelial cell behavior. Further, this difference was also found to be dependent on the particles’ size, morphology and aspect ratio, emphasizing the need of a complementary biological characterization, taking into consideration the endothelial cells’ functionality, to establish the vascular safety of particulate HA. BioMed Central 2018-03-22 /pmc/articles/PMC5863823/ /pubmed/29566760 http://dx.doi.org/10.1186/s12951-018-0357-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Santos, Catarina
Turiel, Suzy
Sousa Gomes, Pedro
Costa, Elísio
Santos-Silva, Alice
Quadros, Paulo
Duarte, José
Battistuzzo, Sílvia
Fernandes, Maria Helena
Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior
title Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior
title_full Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior
title_fullStr Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior
title_full_unstemmed Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior
title_short Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior
title_sort vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863823/
https://www.ncbi.nlm.nih.gov/pubmed/29566760
http://dx.doi.org/10.1186/s12951-018-0357-y
work_keys_str_mv AT santoscatarina vascularbiosafetyofcommercialhydroxyapatiteparticlesdiscrepancybetweenbloodcompatibilityassaysandendothelialcellbehavior
AT turielsuzy vascularbiosafetyofcommercialhydroxyapatiteparticlesdiscrepancybetweenbloodcompatibilityassaysandendothelialcellbehavior
AT sousagomespedro vascularbiosafetyofcommercialhydroxyapatiteparticlesdiscrepancybetweenbloodcompatibilityassaysandendothelialcellbehavior
AT costaelisio vascularbiosafetyofcommercialhydroxyapatiteparticlesdiscrepancybetweenbloodcompatibilityassaysandendothelialcellbehavior
AT santossilvaalice vascularbiosafetyofcommercialhydroxyapatiteparticlesdiscrepancybetweenbloodcompatibilityassaysandendothelialcellbehavior
AT quadrospaulo vascularbiosafetyofcommercialhydroxyapatiteparticlesdiscrepancybetweenbloodcompatibilityassaysandendothelialcellbehavior
AT duartejose vascularbiosafetyofcommercialhydroxyapatiteparticlesdiscrepancybetweenbloodcompatibilityassaysandendothelialcellbehavior
AT battistuzzosilvia vascularbiosafetyofcommercialhydroxyapatiteparticlesdiscrepancybetweenbloodcompatibilityassaysandendothelialcellbehavior
AT fernandesmariahelena vascularbiosafetyofcommercialhydroxyapatiteparticlesdiscrepancybetweenbloodcompatibilityassaysandendothelialcellbehavior